A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(44 sites)

China

Anhui Provincial Hospital, Hefei, Anhui

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing Municipality

Peking Union Medical College Hospital, Beijing, Beijing Municipality

Beijing Youan Hosptital,Capital Medical University, Beijing, Beijing Municipality

Beijing Cancer Hospital, Beijing, Beijing Municipality